Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024
Risk of Parkinson Disease Among Service Members at Marine Corps Base Camp Lejeune
JAMA Neurol 80:673-681, Goldman,S.M.,et al, 2023
The Phenotypic Continuum of ATP1A3-Related Disorders
Neurol 99:e1511-e1526, Vezyroglou,A., et al, 2022
Tics and Functional Tic-Like Movements
Neurol 93:750-758, Ganos, C.,et al, 2019
Cranial Cavernous Malformations
Stroke 49:1029-1035, Stapleton, C.J. & Barker, F.G., 2018
Viral Hepatitis and Parkinson Disease
Neurol 88:1630-1633, Pakpoor, J.,et al, 2017
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Exploring the Association Between Rosacea and Parkinson Disease
JAMA Neurol 73:529-534, Egeberg, A.,et al, 2016
Parkinson Disease Subtypes
JAMA 71:499-504, Thenganatt, M. & Jankovic, J., 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Cluster Headache
BMJ 344:e2407, Nesbitt,A.D.,et al, 2012
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Use of Ibuprofen and Risk of Parkinson Disease
Neurol 76:863-869, Gao,X.,et al, 2011
Drug-Resistant Epilepsy
NEJM 365:919-26, Kwan, P.,et al, 2011
Tourettes Syndrome
NEJM 363:2332-2338, Kurlan,R., 2010
What Predicts Mortality in Parkinson Disease? A Prospective Population-Based Long-Term Study
Neurol 75:1270-1276, Forsaa,E.B.,et al, 2010
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Attempted and Completed Suicides After Subthalamic Nucleus Stimulation for Parkinsons Disease
JNNP 79:952-954, Soulas,T.,et al., 2008
Increased Risk of Parkinsonism in Women Who Underwent Oophorectomy Before Menopause
Neurol 70:200-209, Rocca,W.A.,et al, 2008
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
Association of Olfactory Dysfunction With Risk for Future Parkinsons Disease
Ann Neurol 63:167-173,132, Ross,G.W.,et al, 2008
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Gout and Risk of Parkinson Disease: A Prospective Study
Neurol 69:1696-1700, Alonso,A.,et al, 2007
Parkinson Disease, 10 Years After Its Genetic Revolution: Multiple Clues to a Complex Disorder
Neurol 69:2093-2104, Klein,C. &Schlossmacher,M.G., 2007
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Individual Dopaminergic Neurons Show Raised Iron Levels in Parkinson Disease
Neurol 68:1820-1825, Oakley,A.E.,et al, 2007
Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Arch Neurol 64:820-824, Kleiner-Fisman,G. &Fisman,D.N., 2007
Gender Differences in Parkinsons Disease
JNNP 78:819-824,787, Haaxma,C.A.,et al, 2007
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
Pesticide Exposure and Risk for Parkinsons Disease
Ann Neurol 60:197-203, Ascherio,A.,et al, 2006
Collaborative Analysis of a-Synuclein Gene Promotor Variability and Parkinson Disease
JAMA 296:661-670, Maraganore,D.M.,et al, 2006
Occupation and Parkinsonism in Three Movement Disorders Clinics
Neurol 65:1430-1435, Goldman,S.M.,et al, 2005
Excessive Daytime Sleepiness and Subsequent Development of Parkinson Disease
Neurol 65:1442-1446, Abbott,R.D.,et al, 2005
Idiopathic Hyposmia As a Preclinical Sign of Parkinson's Disease
Ann Neurol 56:173-181,169, Ponsen,M.M.,et al, 2004
Pathogenetic Mechanisms of Parkin in Parkinson's Disease
Lancet 364:722-724, Hattori,N. &Mizuno,Y., 2004
Pathological Gambling Associated with Dopamine Agonist Therapy in Parkinson's
Neurol 61:422-423, Driver-Dunckley,E.,et al, 2003
Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease
Arch Neurol 60:1059-1064,1043, Chen,H.,et al, 2003
Incidence and Prediction of Falls in Parkinson's Disease: A Prospecitve Multidisciplinary Study
JNNP 72:721-725, Wood,B.H.,et al, 2002
Intakes of Vitamins E and C, Carotenoids, Vitamin Supplements, and PD Risk
Neurol 59:1161-1169, Zhang,S.M.,et al, 2002
Mitochondrial Therapy for Parkinson Disease
Arch Neurol 59:1523, Rosenberg,R.N., 2002
Complications of Gamma Knife Surgery for Parkinson Disease
Arch Neurol 58:1995-2002,1970, Okun,M.S.,et al, 2001
Welding-Related Parkinsonism
Neurol 56:8-13,4, Racette,B.A.,et al, 2001
Subclinical Dopaminergic Dysfunction in Asymptomatic Parkinson's Disease Patients' Relatives with a Decreased Sense of Smell
Ann Neurol 50:34-41, Berendse,H.W.,et al, 2001
Susceptibility to Neuroleptic Malignant Syndrome in Parkinson's Disease
Neurol 52:777-781, Ueda,M.,et al, 1999
Clinical Correlates of Vascular Parkinsonism
Arch Neurol 56:98-102, Winikates,J.&Jancovic,J., 1999
Use of Placebo Surgery in Controlled Trials of a Cellular-Based Therapy for Parkinson's Disease
NEJM 341:988-992, Freeman,T.B.,et al, 1999